Document Detail

CCR3 antagonists: a survey of the patent literature.
MedLine Citation:
PMID:  19637977     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Since the mid-1990s, there has been significant effort invested in the discovery and clinical development of CC chemokine receptor-3 (CCR3) antagonists as potential therapeutics for airway disease. OBJECTIVES/METHODS: A patent literature review is presented of small molecule CCR3 antagonists comprising the years 2004 to the present. The patent searches were conducted using Derwent Discovery (World patent index) and PCT publication databases. RESULTS/CONCLUSION: At least two small molecule compounds have been reported to advance into clinical trials. However, data that support a definitive proof-of-concept in humans have yet to be disclosed. Nevertheless, patents from various pharmaceutical companies have continued to emerge, revealing diverse chemical classes of potent CCR3 antagonists and reflecting a continued broad interest in this area.
Leyi Gong; Robert S Wilhelm
Related Documents :
8224297 - The spectrum of ocular toxocariasis.
7785717 - Using the case method to develop clinical reasoning skills in problem-based learning.
21431647 - Cytogenetic analysis and reporting.
16082127 - Clinical features and rapid plasma reagin antibody titers in spontaneous and experiment...
16494187 - Metastatic myxoid liposarcoma in the mesentery: what is debated? case report and a revi...
9792087 - Breakdowns on the path of chronic illness: opportunities for learning.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on therapeutic patents     Volume:  19     ISSN:  1744-7674     ISO Abbreviation:  Expert Opin Ther Pat     Publication Date:  2009 Aug 
Date Detail:
Created Date:  2009-07-29     Completed Date:  2009-11-03     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9516419     Medline TA:  Expert Opin Ther Pat     Country:  England    
Other Details:
Languages:  eng     Pagination:  1109-32     Citation Subset:  IM    
Department of Medicinal Chemistry, Roche Palo Alto LLC, Palo Alto, CA 94304, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Interleukin-5 / antagonists & inhibitors
Morpholines / pharmacology
Patents as Topic*
Piperidines / pharmacology
Pyrrolidines / pharmacology
Receptors, CCR3 / antagonists & inhibitors*
Reg. No./Substance:
0/Interleukin-5; 0/Morpholines; 0/Piperidines; 0/Pyrrolidines; 0/Receptors, CCR3

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Targeting MAPK (Ras/ERK) and PI3K/Akt pathways in pituitary tumorigenesis.
Next Document:  Assessment methods of inhaled aerosols: technical aspects and applications.